AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2011
Sep 26, 2011
35334_dirs_2011-09-26_97c79bcb-4722-47db-82bc-6f16b16bb618.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2011-09-23
Reporting Person: Cavalli Ralph Christopher (VP, Quality Control)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-09-23 | Options to buy Common Stock | $0.37 | J | 40000 | Acquired | 2021-09-15 | Common Stock (40000) | Direct |
Footnotes
F1: Options acquired as a result of employment agreement.
More from AIM ImmunoTech Inc.
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 14